Camp4 Therapeutics vs Coya Therapeutics
CAMP and COYA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAMP and COYA compare
Camp4 Therapeutics is the larger company, worth 3.2 times as much as Coya Therapeutics ($238M against $73.4M).
Camp4 Therapeutics grew revenue faster over the last twelve months (39.9% versus 17.6% for Coya Therapeutics).
Coya Therapeutics keeps more of each dollar of sales as profit, with a net margin of −643% compared with −2276% at Camp4 Therapeutics.
Coya Therapeutics scores higher on the StockData Score (7 against 6 for Camp4 Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAMP | COYA |
|---|---|---|
| Size and price | ||
| Market cap | $238M | $73.4M |
| Share price | $3.80 | $3.13 |
| Change, 1 year | −13.4% | −48.6% |
| Change, 5 years | −98.3% | – |
| Beta (5Y) | 2.72 | 1.19 |
| Employees | 48 | 8 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 44.8× | 15.7× (better) |
| P/B | 2.2× | 2.2× (better) |
| FCF yield | −11.1% | – |
| Fair value | $2.42 | $2.54 |
| Margin of safety | −57.2% | −23.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 39.9% (better) | 17.6% |
| Profitability | ||
| Operating margin | −1001% | −675% (better) |
| Net margin | −2276% | −643% (better) |
| FCF margin | −496% | – |
| Return on equity | −146% | −99.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.42 | 7.24 (better) |
| Altman Z-score | 1.11 | 3.07 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 33.1% |
| Held by insiders | 21.7% | 5.1% |
| Insider net buying, 12 months | −$2.4M | – |
| Short interest, % of float | 6.6% | 6.3% |
Go deeper
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
- COYA stock overview
- COYA income statement
- COYA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.